Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer
Use this link to cite this item : https://ir.lib.hiroshima-u.ac.jp/00028880
ID | 28880 |
file | |
creator |
Matsuura, Kanji
Kashiwado, Kozo
Fujita, Kazushi
Akagi, Yukio
Yuki, Shintarou
Murakami, Yuji
Wadasaki, Koichi
Monzen, Yoshio
Ito, Atsushi
Kagemoto, Masayuki
Mori, Masaki
Ito, Katsuhide
|
subject | Involved-field radiation therapy (IFRT)
Elective nodal irradiation (ENI)
Three-dimensional conformal radiation therapy (3DCRT)
Non-small-cell lung cancer (NSCLC)
Carboplatin (CBDCA)
Paclitaxel (PTX)
|
NDC |
Medical sciences
|
abstract | We aimed to evaluate the feasibility and efficacy of hypofractionated involved-field radiation therapy (IFRT) omitting elective nodal irradiation (ENI) with concurrent chemotherapy for locally advanced non-small-cell lung cancer (NSCLC). Between July 2004 and July 2006, ten patients with locally advanced NSCLC were included in this study. One had stage IIIA and 9 had stage IIIB disease. The treatment consisted of IFRT in fractions of 2.5 Gy and weekly carboplatin (CBDCA)/paclitaxel (PTX). Hypofractionated IFRT with a median total dose of 65 Gy with median percent total lung volume exceeding 20 Gy (V20) of 20.2%, and a median of five courses of chemotherapy with weekly CBDCA (area under the curve, 1.5-2.0)/PTX (30-35 mg/m(2)) were given to all patients. The median survival time and the 1-, 2-, and 3-year overall survival rates were 29.5 months and 90.0%, 58.3%, and 43.8%, respectively. No elective nodal failure was encountered during the median follow up of 18.2 months. No acute or late toxicities of grade 3 or worse were observed. No in-field recurrence occurred in the group with a total dose of 67.5 Gy or more, but there was such recurrence in 83.3% of those in the group with less than 67.5 Gy. Hypofractionated IFRT with weekly CBDCA/PTX was a feasible treatment regimen. Hypofractionated IFRT with a total dose of 67.5 Gy or more could be a promising modality to improve the treatment results in patients with locally advanced NSCLC.
|
journal title |
International Journal of Clinical Oncology
|
volume | Volume 14
|
issue | Issue 5
|
start page | 408
|
end page | 415
|
date of issued | 2009-10-24
|
publisher | Springer Tokyo
|
issn | 1341-9625
|
ncid | |
publisher doi | |
language |
eng
|
nii type |
Journal Article
|
HU type |
Journal Articles
|
DCMI type | text
|
format | application/pdf
|
text version | author
|
rights | Copyright (c) 2009 Springer
|
relation | The original publication is available at www.springerlink.com
|
relation url | |
department |
Graduate School of Biomedical Science
|